Atrium Therapeutics, Inc. Common Stock (RNA) — Cash Flow Reinvestment Rate
Atrium Therapeutics, Inc. Common Stock (RNA) has a Cash Flow Reinvestment Rate of 3.15x as of December 2023, reinvesting $51.90 Million (capex $863.00K plus investments $51.04 Million) from operating cash flow of $16.50 Million. Explore Atrium Therapeutics, Inc. Common Stock (RNA) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Atrium Therapeutics, Inc. Common Stock Cash Flow Reinvestment Rate (2019–2019)
Historical reinvestment intensity for Atrium Therapeutics, Inc. Common Stock across 1 annual periods. Also explore Atrium Therapeutics, Inc. Common Stock total assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Atrium Therapeutics, Inc. Common Stock (2019–2019)
Year-by-year capital reinvestment analysis for Atrium Therapeutics, Inc. Common Stock. For live market cap and broader valuation context, see Atrium Therapeutics, Inc. Common Stock (RNA) total market value.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2019 | 0.19x | $470.00K | $2.49 Million | $235.00K | — |